103 results
Page 3 of 6
8-K
EX-10.3
a3flbyyjqsumna
13 Jan 21
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
caq8imfwmjda9
11 Dec 20
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
8:31am
8-K
EX-10.1
79y2wg8u
13 Nov 20
Termination of a Material Definitive Agreement
4:02pm
8-K
EX-99.1
2cqfs1opgim 0uddtit
10 Nov 20
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results
4:22pm
8-K
EX-10.1
w3kka gmas2u51zzp8u
2 Oct 20
Departure of Directors or Certain Officers
4:49pm
8-K
EX-99.1
dan aj1u3nps
10 Aug 20
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results
4:09pm
S-8
EX-4.2
0i1k679cj6lqwh1bg8d
26 Jun 20
Registration of securities for employees
5:01pm
424B5
8nmwat09nbcn 944a
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
23b59r894yvquxnv7
23 Jun 20
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.2
h2hokp ee
8 Jun 20
Regulation FD Disclosure
5:04pm
8-K
EX-99.1
dwkw07tbsjwp5eyfv
12 May 20
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results
4:05pm
8-K
EX-99.1
iksvsf
4 Mar 20
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
4:17pm
8-K
EX-99.1
8h7fyzs9ozvwkofan06
6 Jan 20
Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome
5:01pm
8-K
EX-99.1
npgc226be2qe48kesow
13 Nov 19
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results
6:10am
424B5
3563s6h
25 Oct 19
Prospectus supplement for primary offering
12:00am